Pazopanib in metastatic renal cancer: a "real-world" experience at National Cancer Institute "Fondazione G. Pascale"

• Main Authors: Sabrina Chiara Cecere (Author), Sabrina Rossetti (Author), Carla Cavaliere (Author), Chiara Della Pepa (Author), Marilena Di Napoli (Author), Anna Crispo (Author), Gelsomina Iovane (Author), Raffaele Piscitelli (Author), Domenico Sorrentino (Author), Gennaro Ciliberto (Author), Piera Maiolino (Author), Paolo Muto (Author), Sisto Perdonà (Author), Massimiliano Berretta (Author), Sandro Pignata (Author), Gaetano Facchini (Author), Carmine D'Aniello (Author)
• Format: Book
• Published: Frontiers Media S.A., 2016-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Pazopanib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma. The present study analyzed the outcomes of pazopanib in first-line treatment of mRCC, in a single Italian cancer center. In the light of the retrospective,...